mecasermin: Clinical Trials

8 trials of mecasermin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated. 8 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 5, Terminated 3
Phase 25Completed 4, Terminated 1

Follow mecasermin: new trials by email Literature Review of mecasermin trials Research Report on mecasermin

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency
Increlex - Short Stature
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati72015-12-212024-02-28
Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack
mecasermin, 0.9% sodium chloride injection - Heart Failure, Myocardial Infarction
Phase 1 / Phase 2CompletedUniversity College Cork472011-10-012017-03-30
Effects of IGF-I in HIV Metabolic Disease
mecasermin, Placebo control - HIV Lipodystrophy
Phase 1TerminatedUniversity of Texas Southwestern Medical Center162011-06-012016-03-23
Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
rhIGF-1 - Rett Syndrome
Phase 1CompletedBoston Children's Hospital122010-12-012017-06-22
Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy
IGF-1 - Duchenne Muscular Dystrophy
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati442010-11-012021-01-20
IGF-1 Therapy in Patients With Cystic Fibrosis
recombinant human IGF-1, Placebo - Cystic Fibrosis
Phase 1TerminatedStony Brook University152008-06-012013-01-28
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Increlex - Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 / Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)62007-06-012015-07-03
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
RhIGF-1 - Anorexia Nervosa
Phase 1 / Phase 2CompletedMassachusetts General Hospital162007-03-012021-11-18

Conditions studied

Anorexia Nervosa (1)  ·  Body Weight (1)  ·  Cystic Fibrosis (1)  ·  Dwarfism (1)  ·  Failure to Thrive (1)  ·  Heart Failure (1)  ·  Muscular Dystrophy, Duchenne (1)  ·  Myocardial Infarction (1)  ·  Rett Syndrome (1)  ·  X-Linked Combined Immunodeficiency Diseases (1)

Sponsors

Children's Hospital Medical Center, Cincinnati (2)  ·  Boston Children's Hospital (1)  ·  Massachusetts General Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Stony Brook University (1)  ·  University College Cork (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (6)  ·  Ireland (1)  ·  Netherlands (1)

Top investigators

Gajanathan Muthuvel, MD (1)  ·  Madhu Misra (1)  ·  Meilan Rutter, MD (1)  ·  Mustafa Sahin, MD, PhD (1)  ·  Noel Caplice, MB, PhD (1)  ·  Philippe Backeljauw, MD (1)  ·  Roy J Kim, MD, MPH (1)  ·  Suk S De Ravin, M.D. (1)  ·  Thomas A Wilson, MD (1)

Results publications

PMID 29029190, PMID 36646053